Technology
Health
Biotechnology

REGENXBIO

$50.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.55 (3.15%) As of 12:52 PM EDT today
+$1.55 (3.15%) Today

Why Robinhood?

You can buy or sell REGENXBIO and other stocks, options, ETFs, and crypto commission-free!

About RGNX

REGENXBIO Inc. Common Stock, also called REGENXBIO, is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Read More The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Employees
192
Headquarters
Rockville, Maryland
Founded
2008
Market Cap
1.80B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
467.62K
High Today
$51.00
Low Today
$49.04
Open Price
$49.51
Volume
208.70K
52 Week High
$83.45
52 Week Low
$38.56

Collections

Technology
Health
Biotechnology
Therapy
2015 IPO
US
North America

RGNX Earnings

-$0.89
$0.42
$1.73
$3.04
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.